Syntax Bio
Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine
$14.4MSeries A+
Role not disclosedDB
DCVC Bio
Activity from announced rounds
Activity in this selectionSeries A
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $111.4M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionLatus Bio, Inc.
Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2
$97MSeries A
Role not disclosed